Literature DB >> 29578532

Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation.

Prabhakaran Kumar1, Alejandra Marinelarena1, Divya Raghunathan1, Vandhana K Ragothaman1, Shikha Saini1, Palash Bhattacharya1, Jilao Fan, Alan L Epstein2, Ajay V Maker1,3, Bellur S Prabhakar4.   

Abstract

Regulatory T cells (Tregs) play a pivotal role in immune-tolerance, and loss of Treg function can lead to the development of autoimmunity. Natural Tregs generated in the thymus substantially contribute to the Treg pool in the periphery, where they suppress self-reactive effector T cells (Teff) responses. Recently, we showed that OX40L (TNFSF4) is able to drive selective proliferation of peripheral Tregs independent of canonical antigen presentation (CAP-independent) in the presence of low-dose IL-2. Therefore, we hypothesized that OX40 signaling might be integral to the TCR-independent phase of murine and human thymic Treg (tTreg) development. Development of tTregs is a two-step process: Strong T-cell receptor (TCR) signals in combination with co-signals from the TNFRSF members facilitate tTreg precursor selection, followed by a TCR-independent phase of tTreg development in which their maturation is driven by IL-2. Therefore, we investigated whether OX40 signaling could also play a critical role in the TCR-independent phase of tTreg development. OX40-/- mice had significantly reduced numbers of CD25-Foxp3low tTreg precursors and CD25+Foxp3+ mature tTregs, while OX40L treatment of WT mice induced significant proliferation of these cell subsets. Relative to tTeff cells, OX40 was expressed at higher levels in both murine and human tTreg precursors and mature tTregs. In ex vivo cultures, OX40L increased tTreg maturation and induced CAP-independent proliferation of both murine and human tTregs, which was mediated through the activation of AKT-mTOR signaling. These novel findings show an evolutionarily conserved role for OX40 signaling in tTreg development and proliferation, and might enable the development of novel strategies to increase Tregs and suppress autoimmunity.

Entities:  

Keywords:  IL-2; OX40L; Thymic Tregs; Treg proliferation; maturation

Mesh:

Substances:

Year:  2018        PMID: 29578532      PMCID: PMC6355936          DOI: 10.1038/cmi.2018.8

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  61 in total

1.  Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide.

Authors:  M S Jordan; A Boesteanu; A J Reed; A L Petrone; A E Holenbeck; M A Lerman; A Naji; A J Caton
Journal:  Nat Immunol       Date:  2001-04       Impact factor: 25.606

Review 2.  Thymic and peripheral differentiation of regulatory T cells.

Authors:  Hyang-Mi Lee; Jhoanne Lynne Bautista; Chyi-Song Hsieh
Journal:  Adv Immunol       Date:  2011       Impact factor: 3.543

3.  Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor.

Authors:  Julien C Marie; Denny Liggitt; Alexander Y Rudensky
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

4.  Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment.

Authors:  Damien Bresson; Georgia Fousteri; Yulia Manenkova; Michael Croft; Matthias von Herrath
Journal:  J Autoimmun       Date:  2011-11-06       Impact factor: 7.094

5.  Thymic B cells promote thymus-derived regulatory T cell development and proliferation.

Authors:  Fang-Ting Lu; Wei Yang; Yin-Hu Wang; Hong-Di Ma; Wei Tang; Jing-Bo Yang; Liang Li; Aftab A Ansari; Zhe-Xiong Lian
Journal:  J Autoimmun       Date:  2015-06-11       Impact factor: 7.094

6.  Effector T cells boost regulatory T cell expansion by IL-2, TNF, OX40, and plasmacytoid dendritic cells depending on the immune context.

Authors:  Audrey Baeyens; David Saadoun; Fabienne Billiard; Angéline Rouers; Sylvie Grégoire; Bruno Zaragoza; Yenkel Grinberg-Bleyer; Gilles Marodon; Eliane Piaggio; Benoît L Salomon
Journal:  J Immunol       Date:  2014-12-29       Impact factor: 5.422

7.  Age-dependent divergent effects of OX40L treatment on the development of diabetes in NOD mice.

Authors:  Christine S Haddad; Palash Bhattacharya; Khaled Alharshawi; Alejandra Marinelarena; Prabhakaran Kumar; Osama El-Sayed; Hatem A Elshabrawy; Alan L Epstein; Bellur S Prabhakar
Journal:  Autoimmunity       Date:  2016-05-31       Impact factor: 2.815

8.  Human regulatory T-cell development is dictated by Interleukin-2 and -15 expressed in a non-overlapping pattern in the thymus.

Authors:  Iris Caramalho; Vânia Nunes-Silva; Ana R Pires; Catarina Mota; Ana I Pinto; Helena Nunes-Cabaço; Russell B Foxall; Ana E Sousa
Journal:  J Autoimmun       Date:  2014-12-04       Impact factor: 7.094

9.  IL-2R signaling is essential for functional maturation of regulatory T cells during thymic development.

Authors:  Guoyan Cheng; Aixin Yu; Michael J Dee; Thomas R Malek
Journal:  J Immunol       Date:  2013-01-11       Impact factor: 5.422

10.  T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR.

Authors:  Stephan Sauer; Ludovica Bruno; Arnulf Hertweck; David Finlay; Marion Leleu; Mikhail Spivakov; Zachary A Knight; Bradley S Cobb; Doreen Cantrell; Eric O'Connor; Kevan M Shokat; Amanda G Fisher; Matthias Merkenschlager
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-28       Impact factor: 11.205

View more
  17 in total

1.  OX40L-JAG1-Induced Expansion of Lineage-Stable Regulatory T Cells Involves Noncanonical NF-κB Signaling.

Authors:  Prabhakaran Kumar; Swarali Surendra Lele; Vandhana K Ragothaman; Divya Raghunathan; Alan L Epstein; Shigeru Chiba; Bellur S Prabhakar
Journal:  J Immunol       Date:  2019-11-08       Impact factor: 5.422

Review 2.  A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.

Authors:  Prabhakaran Kumar; Palash Bhattacharya; Bellur S Prabhakar
Journal:  J Autoimmun       Date:  2018-08-31       Impact factor: 7.094

Review 3.  Neuroinflammation: Extinguishing a blaze of T cells.

Authors:  Nail Benallegue; Hania Kebir; Jorge I Alvarez
Journal:  Immunol Rev       Date:  2022-07-31       Impact factor: 10.983

4.  Antibody-Mediated Targeting of a Hybrid Insulin Peptide Toward Neonatal Thymic Langerin-Positive Cells Enhances T-Cell Central Tolerance and Delays Autoimmune Diabetes.

Authors:  Yong Lin; Jelena Perovanovic; Yuelin Kong; Botond Z Igyarto; Sandra Zurawski; Dean Tantin; Gerard Zurawski; Maria Bettini; Matthew L Bettini
Journal:  Diabetes       Date:  2022-08-01       Impact factor: 9.337

Review 5.  Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells.

Authors:  Prabhakaran Kumar; Shikha Saini; Saad Khan; Swarali Surendra Lele; Bellur S Prabhakar
Journal:  Cell Immunol       Date:  2018-09-29       Impact factor: 4.868

Review 6.  Maternal and fetal T cells in term pregnancy and preterm labor.

Authors:  Derek Miller; Meyer Gershater; Rebecca Slutsky; Roberto Romero; Nardhy Gomez-Lopez
Journal:  Cell Mol Immunol       Date:  2020-05-28       Impact factor: 11.530

7.  Bcl10 is required for the development and suppressive function of Foxp3+ regulatory T cells.

Authors:  Dandan Yang; Xueqiang Zhao; Xin Lin
Journal:  Cell Mol Immunol       Date:  2019-10-08       Impact factor: 11.530

8.  Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo.

Authors:  Manuel F Fernandez; Guilin Qiao; Kiara Tulla; Bellur S Prabhakar; Ajay V Maker
Journal:  J Surg Res       Date:  2021-02-22       Impact factor: 2.417

Review 9.  MTOR Signaling and Metabolism in Early T Cell Development.

Authors:  Guy Werlen; Ritika Jain; Estela Jacinto
Journal:  Genes (Basel)       Date:  2021-05-13       Impact factor: 4.096

Review 10.  Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies.

Authors:  Karolina Stachyra; Monika Dudzisz-Śledź; Elżbieta Bylina; Anna Szumera-Ciećkiewicz; Mateusz J Spałek; Ewa Bartnik; Piotr Rutkowski; Anna M Czarnecka
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.